While body weights, the liver/body weight ratio, and hepatic triglyceride content were not affected (Fig. 7f–i), plasma ALT and AST levels were markedly reduced in the NASH mice treated with ZnPP compared to vehicle control-treated NASH mice (Fig. 7j and k). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.